Cdk4/6 Inhibitors & Endocrine Therapy: Selecting A Regimen

CDK4/6 Inhibitors & Endocrine Therapy: Selecting a Regimen

Targeted Oncology

CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy

CDK4/6 Inhibitors & Endocrine Therapy in Breast Cancer

Targeted Oncology

Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer

Targeted Oncology

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy

Endocrine therapy and CDK4/6 Inhibitors in high-risk HR+ breast cancer

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

CDK4/6 Inhibitors & Endocrine Therapy: Adverse Events

Targeted Oncology

CDK4/6 Inhibitors & Endocrine Therapy: Treatment Resistance

Targeted Oncology

Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical Use

What are CDK 4/6 Inhibitors for Breast Cancer?

Yerbba – Breast Cancer

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNA

Updates on Breast Cancer Treatment: Exploring CDK4/6 Inhibitors & Endocrine Therapy

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

PeerView Oncology

Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review Conference

Total Health | Oncology

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

HR+ Breast Cancer: CDK4/6 Inhibitors & Sites of Metastasis

Picking the right CDK 4/6 inhibitor upfront for metastatic breast cancer.

OncBrothers: Practice-Changing Cancer Discussions